[Form 4] Bio-Techne Corp. Insider Trading Activity

Rhea-AI Filing Summary

Robert V. Baumgartner, a director of Bio-Techne Corporation (TECH), reported transactions on 08/25/2025 in which he exercised 17,040 stock options with an exercise price of $21.84 and immediately sold 17,040 common shares at a weighted average price of $56.21 (sales ranged $55.97–$56.34). The Form 4 shows a temporary increase in beneficial ownership to 61,903 shares after the exercise, and a final beneficial ownership of 44,863 shares following the sale. The filing lists outstanding stock options across multiple grant years with strike prices from $21.84 to $128.81 and various expiration dates, and notes one option vests on the earlier of the one-year anniversary of the 10/24/2024 grant or Bio-Techne's 2025 annual meeting. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Baumgartner.

Positive

• Exercise and sale documented: 17,040 options exercised at $21.84 and sold at a weighted average of $56.21.
• Complete disclosure of holdings: Form 4 lists outstanding options by strike and expiration, providing transparency on potential future dilution.

Negative

• Reported beneficial ownership decreased: final beneficial ownership after the transactions was 44,863 shares.
• Sale price disclosed as a weighted average: the filing notes shares were sold at prices ranging from $55.97 to $56.34, with per-price breakdown not provided in the form.

Insights

Financial Analyst

TL;DR Director exercised options and sold all resulting shares, reducing his reported beneficial ownership to 44,863 shares.

The transactions are routine insider option exercise and sale activity documented on Form 4. The exercise price of $21.84 compared with a weighted sale price of $56.21 shows the director realized intrinsic value per share equal to the spread between those prices. The filing also details the director's remaining option portfolio by strike and expiration, which may affect future dilution timing but no dilution occurred in this reported transaction because exercised shares were sold into the market. This disclosure is material for tracking insider liquidity and current reported holdings but contains no operational or financial results for the company.

Corporate Governance Expert

TL;DR Insider exercised vested options and sold shares; disclosure follows Section 16 reporting requirements.

The Form 4 provides required transparency on beneficial ownership changes: exercise of 17,040 options (exercise price $21.84) and sale of those 17,040 shares (weighted avg $56.21). The report includes a footnote clarifying sale price range and a vesting condition for a recent grant. Filing was executed via power of attorney. There are no indications here of regulatory or governance issues; this is a standard disclosure of option exercise and share disposition by a director.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BAUMGARTNER ROBERT V

(Last) (First) (Middle)

614 MCKINLEY PL NE

(Street)

MINNEAPOLIS MN 55413

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [ TECH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/25/2025		M		17,040	A	$21.84	61,903	D
Common Stock	08/25/2025		S		17,040	D	$56.21(1)	44,863	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$21.84	08/25/2025		M			17,040	10/29/2016	10/28/2025	Common Stock	17,040	$0	0	D
Stock Options (Right to Buy)	$25.3							10/26/2017	10/26/2026	Common Stock	15,940		15,940	D
Stock Options (Right to Buy)	$31.26							10/25/2018	10/26/2027	Common Stock	12,500		12,500	D
Stock Options (Right to Buy)	$44.96							10/24/2019	10/25/2028	Common Stock	7,592		7,592	D
Stock Options (Right to Buy)	$50.41							10/24/2020	10/24/2029	Common Stock	8,044		8,044	D
Stock Options (Right to Buy)	$63.92							10/28/2021	10/29/2030	Common Stock	6,028		6,028	D
Stock Options (Right to Buy)	$128.81							10/27/2022	10/28/2031	Common Stock	2,532		2,532	D
Stock Options (Right to Buy)	$73.94							10/26/2023	10/27/2032	Common Stock	3,460		3,460	D
Stock Options (Right to Buy)	$61.51							10/24/2024	10/26/2033	Common Stock	3,937		3,937	D
Stock Options (Right to Buy)	$68.37							(2)	10/24/2034	Common Stock	3,511		3,511	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.97 to $56.34 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The option vests on the earlier of the one year anniversary of the grant date (10/24/2024) or the date of Bio-Techne's 2025 annual meeting of shareholders.

	/s/ Andrew Nick as Attorney-in-Fact for Robert V. Baumgartner pursuant to Power of Attorney previously filed.	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Bio-Techne director Robert V. Baumgartner report on Form 4 (TECH)?

He exercised 17,040 stock options at an exercise price of $21.84 and sold 17,040 common shares at a weighted average price of $56.21 on 08/25/2025.

What is Robert Baumgartner's beneficial ownership of TECH after the reported transactions?

The Form 4 reports a final beneficial ownership of 44,863 common shares following the transactions.

Were the sales executed at a single price?

No. The filing states the sale price is a weighted average and the shares were sold at prices ranging from $55.97 to $56.34.

What option grants and strike prices does the Form 4 disclose for Mr. Baumgartner?

The filing lists multiple outstanding option grants with strike prices from $21.84 up to $128.81 and various expiration dates (examples include 10/28/2025 and 10/28/2031).

Was the Form 4 signed by Mr. Baumgartner?

The Form 4 was signed by Andrew Nick as Attorney-in-Fact for Robert V. Baumgartner pursuant to a previously filed power of attorney on 08/27/2025.

Does this Form 4 disclose company financial results or guidance?

No. The Form 4 only reports changes in beneficial ownership and outstanding derivative positions; it does not include operational or earnings information.